Regulus Therapeutics Inc. (NASDAQ:RGLS) Director Purchases $20,786.60 in Stock

Regulus Therapeutics Inc. (NASDAQ:RGLS) Director David Baltimore bought 19,610 shares of the stock in a transaction on Thursday, January 30th. The shares were bought at an average cost of $1.06 per share, for a total transaction of $20,786.60. Following the purchase, the director now owns 22,169 shares in the company, valued at $23,499.14. This trade represents a 766.31 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.

Regulus Therapeutics Price Performance

Shares of NASDAQ RGLS opened at $1.00 on Friday. Regulus Therapeutics Inc. has a twelve month low of $0.83 and a twelve month high of $3.79. The firm has a 50-day moving average of $1.46 and a two-hundred day moving average of $1.54.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03). Equities analysts predict that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Regulus Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. NEA Management Company LLC acquired a new stake in shares of Regulus Therapeutics during the third quarter worth $10,154,000. State Street Corp raised its holdings in Regulus Therapeutics by 3.5% during the 3rd quarter. State Street Corp now owns 1,000,998 shares of the biopharmaceutical company’s stock worth $1,572,000 after buying an additional 33,496 shares during the period. Point72 Asset Management L.P. acquired a new stake in Regulus Therapeutics during the 3rd quarter worth about $1,403,000. Victory Capital Management Inc. boosted its holdings in shares of Regulus Therapeutics by 10.4% in the third quarter. Victory Capital Management Inc. now owns 398,866 shares of the biopharmaceutical company’s stock worth $626,000 after buying an additional 37,480 shares during the period. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Regulus Therapeutics in the third quarter worth approximately $204,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Regulus Therapeutics in a research note on Monday, November 11th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.80.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.